Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal.

Introduction: The ILUVIEN® (fluocinolone acetonide) Clinical Evidence in Portugal (ICE-PT) study is a retrospective, multicenter, observational study evaluating the effectiveness and safety of the FAc implant in patients with diabetic macular edema. Methods: Patients included in this study had recei...

Descripción completa

Detalles Bibliográficos
Publicado en:Therapeutic Advances in Ophthalmology Vol. 12; pp. 1 - 10
Autores principales: Carneiro, Angela, Meireles, Angelina, Sousa, João Paulo Castro, Teixeira, Carla
Formato: clinical trial research tables/charts Journal Article
Publicado: Sage Publications Inc. Jan-Dec2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149913702&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 149913702
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        25158414
        LAW0
      jtl: Therapeutic Advances in Ophthalmology
      issn: 25158414
      maglogo: Y
    pubinfo:
      dt: Jan-Dec2020
      vid: 12
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        149913702
        149913702
        149913702
        10.1177/2515841420917768
        149913702
      ppf: 1
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN® clinical evidence study in Portugal.
      aug:
        au:
          Carneiro, Angela
          Meireles, Angelina
          Sousa, João Paulo Castro
          Teixeira, Carla
        affil: Bioengineering, BGKT Consulting Ltd., Huntington, NY, USA
      sug:
        subj:
          Vitreous Body
          Eye Diseases
          Diabetes Mellitus
          Ophthalmic Solutions Administration and Dosage
          Ophthalmic Solutions Pharmacodynamics
          Treatment Outcomes
          Human
          Clinical Trials
          Portugal
          Visual Acuity
          Tomography, Optical Coherence
          Descriptive Statistics
          Data Analysis Software
          Diabetic Retinopathy
          Macular Degeneration
          Retrospective Design
          Multicenter Studies
          Nonexperimental Studies
          Wilcoxon Rank Sum Test
          T-Tests
          Male
          Female
          Middle Age
          Aged
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Introduction: The ILUVIEN® (fluocinolone acetonide) Clinical Evidence in Portugal (ICE-PT) study is a retrospective, multicenter, observational study evaluating the effectiveness and safety of the FAc implant in patients with diabetic macular edema. Methods: Patients included in this study had received the 0.2 µg/day fluocinolone acetonide implant for the treatment of diabetic macular edema and had measurements of visual acuity and retinal thickness assessed by optical coherence tomography for at least 12 months pre- and post-fluocinolone acetonide implant administration, with ≥2 follow-up visits. Outcomes measured included visual acuity, central foveal thickness, and intraocular pressure. Results: There was a significant increase in mean visual acuity compared with baseline at 3, 6, 9, and 12 months post-fluocinolone acetonide in both the overall study population and the pseudophakic subgroup (p < 0.05 at all time points in both groups). A significant reduction in mean central foveal thickness compared with baseline was seen in the overall study population at 3, 6, 9, and 12 months post-fluocinolone acetonide (p < 0.05 at all time points). At 12-month post-fluocinolone acetonide, a small but significant intraocular pressure increase of 1.0 mmHg was seen in the overall study population. Conclusion: The results of this analysis show that switching from the current standard of care to the fluocinolone acetonide implant leads to beneficial effects in terms of vision and retinal structure in patients with diabetic macular edema and that patients benefited from FAc implant administration, regardless of lens status.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N